ArticleCureus2025
Nocebo Effect During Letrozole Desensitization: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A novel provocation protocol to identify nocebo effects in clinical practice-a proof-of-concept n-of-1 study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report describes the case of a 46-year-old woman with breast cancer and a history of multiple drug hypersensitivity reactions, who developed atypical allergic-like symptoms with three different adjuvant endocrine therapy regimens. As the use of an aromatase inhibitor was considered essential for her treatment, a three-day desensitization protocol to letrozole was implemented. During the protocol, she developed pruritic erythema following placebo administration. Despite this, the protocol was completed, with only mild side effects (oropharyngeal pruritus and headache), which were managed symptomatically. A diagnosis of nocebo reaction was disclosed to the patient after the desensitization process. She continued daily treatment with 2.5 mg of letrozole without further hypersensitivity complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.